Cite

HARVARD Citation

    Pagan, F. et al. (n.d.). Nilotinib is reasonably safe and may halt the disease progression in moderately severe Parkinson's disease patients. Parkinsonism & related disorders. pp. e71-. [Online]. 
  
Back to record